Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
Active, not recruiting · NCT03653052 · Registry updated 2025-04-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal disorder, neoplasm | Active, not recruiting | Phase 2 | 2025-04-24 | NCT03653052 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Simon C Pacey, MD | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cambridge University Hospitals NHS Foundation Trust | Cambridge | United Kingdom | 34 |